Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms

Table 2

Metabolic characteristics of patients with type 2 diabetes and nonalcoholic fatty liver disease by liraglutide use.

Characteristic	Before	After
General and biochemical markers	49	49
BMI, kg/m2	28.76 (26.93, 30.9)	27.72 (26.79, 30.85)	0.011
FBG, mmol/L	9.99 (7.49, 12.88)	8.13 (6.57, 11.30)	0.496
HbA1c, %	10 (8.57, 11.4)	8.7 (7.8, 9.55)	0.009
LDL, mmol/L	2.68 ± 0.87	2.34 ± 0.80	0.433
HDL, mmol/L	0.84 (0.72, 0.98)	0.96 (0.81, 1.088)	0.023
ALT, IU/L	25 (18, 42)	24 (15, 37)	0.332
AST, IU/L	21 (15, 33)	18 (16.26.2)	0.210
ALP, IU/L	81.41 ± 30.19	77.33 ± 15.5	0.244
r-GT, IU/L	32.35 (21.25, 67.78)	34.6 (19, 42)	0.856
eGFR, ml/min/1.73 m^2	115.23 ± 51.74	109.96 ± 31.74	0.102
FT3, pmol/L	4.76 (4.34, 5.28)	4.51 (4.18, 5.11)	0.826
FT4, pmol/L	14.17 (12.49, 16.07)	13.24 (11.92, 14.47)	0.975
TSH, mIU/L	1.94 (1.12, 2.95)	1.46 (0.89, 2.04)	0.019
Use of hypoglycemic drugs
Insulin (N, %)	21 (42.9%)	18 (36.7%)	0.536
Metformin (N, %)	29 (59.2%)	34 (69.4%)	0.292
Thiazolidinediones (N, %)	3 (6.1%)	1 (2.0%)	0.617
Sulfonylureas/glinides (N, %)	3 (6.1%)	1 (2.0%)	0.617
Glucosidase inhibitors	11 (22.4%)	7 (14.3%)	0.545
SGLT2 inhibitors	29 (59.2%)	27 (55.1%)	0.683